Literature DB >> 11035325

Expectant management of severe preterm preeclampsia: is intrauterine growth restriction an indication for immediate delivery?

M F Chammas1, T M Nguyen, M A Li, B S Nuwayhid, L C Castro.   

Abstract

OBJECTIVE: Expectant management of severe preterm preeclampsia is gaining widespread acceptance in clinical practice. The objective of our study was 2-fold-to determine the frequency of fetal deterioration with expectant management of severe preterm preeclampsia and to evaluate whether the presence of intrauterine growth restriction on admission is associated with a shorter admission-to-delivery interval or more deliveries resulting from nonreassuring fetal status in comparison with pregnancies with preeclampsia but without intrauterine growth restriction. STUDY
DESIGN: This was an observational study of women with singleton pregnancies at <34 completed weeks' gestation who were admitted to the hospital with the diagnosis of severe preeclampsia and managed expectantly. Fetal status on admission, admission-to-delivery interval, indication for delivery, and neonatal outcome were examined.
RESULTS: Forty-seven women were studied during a 3-year period (1996-1999). Gestational age at admission was 29.8 +/- 2.6 weeks. The mean admission-to-delivery interval for the entire group was 6.0 +/- 5.1 days; in 42.5% delivery was for fetal indications. In comparison with the absence of intrauterine growth restriction, the presence of intrauterine growth restriction at admission resulted in a significantly shorter admission-to-delivery interval (3.1 +/- 2.1 vs 6.6 +/- 6.1 days; P <.05). Most fetuses with intrauterine growth restriction (85.7%) were delivered before 1 week. Although 57% of fetuses with intrauterine growth restriction were delivered for fetal indications, versus 39% of fetuses without intrauterine growth restriction, these rates were not found to be significantly different. Neonatal outcomes, as reflected by Apgar scores, number of admissions to and duration of stay in the neonatal intensive care unit, and neonatal mortality rates, were similar.
CONCLUSION: Pregnancies complicated by severe preterm preeclampsia and the presence of intrauterine growth restriction at admission may not benefit from expectant management beyond the 48 hours needed for betamethasone to act. Furthermore, all patients may benefit from close fetal monitoring before delivery because of the high rate of intervention for deteriorating fetal status.

Entities:  

Mesh:

Year:  2000        PMID: 11035325     DOI: 10.1067/mob.2000.109049

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  An analysis of expectant management in women with early-onset preeclampsia in China.

Authors:  Q Chen; F Shen; Y F Gao; M Zhao
Journal:  J Hum Hypertens       Date:  2014-10-23       Impact factor: 3.012

2.  Maternal and perinatal outcome during expectant management of severe pre-eclampsia between 24 and 34 weeks of gestation.

Authors:  M K Swamy; Kamal Patil; Shailaja Nageshu
Journal:  J Obstet Gynaecol India       Date:  2012-10-23

3.  Diagnosis and management of pre-eclampsia: an update.

Authors:  Judi A Turner
Journal:  Int J Womens Health       Date:  2010-09-30

4.  Adverse maternal and neonatal outcomes among women with preeclampsia with severe features <34 weeks gestation with versus without comorbidity.

Authors:  Kartik K Venkatesh; Robert A Strauss; Daniel J Westreich; John M Thorp; David M Stamilio; Katherine L Grantz
Journal:  Pregnancy Hypertens       Date:  2020-03-10       Impact factor: 2.899

5.  The Role of PPARs in Placental Immunology: A Systematic Review of the Literature.

Authors:  Stefan Hutter; Julia Knabl; Ulrich Andergassen; Udo Jeschke
Journal:  PPAR Res       Date:  2013-03-10       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.